Back to resultsAlternate-Day Buprenorphine Administration. Phase VIII - 9
Primary Purpose
Opioid-Related Disorders
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Buprenorphine
Sponsored by
About this trial
This is an interventional treatment trial for Opioid-Related Disorders
Eligibility Criteria
Please contact site for information.
Sites / Locations
- Treatment Research Center
Outcomes
Primary Outcome Measures
Drug use
Opioid withdrawal
Opioid agonist effects
Dose choice
Secondary Outcome Measures
Full Information
NCT ID
NCT00000227
First Posted
September 20, 1999
Last Updated
May 5, 2016
Sponsor
University of Vermont
Collaborators
National Institute on Drug Abuse (NIDA)
1. Study Identification
Unique Protocol Identification Number
NCT00000227
Brief Title
Alternate-Day Buprenorphine Administration. Phase VIII - 9
Official Title
Alternate-Day Buprenorphine Administration. Phase VIII
Study Type
Interventional
2. Study Status
Record Verification Date
July 1996
Overall Recruitment Status
Completed
Study Start Date
August 1994 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
University of Vermont
Collaborators
National Institute on Drug Abuse (NIDA)
4. Oversight
5. Study Description
Brief Summary
The purpose of this study is to evaluate open buprenorphine dosing with dose choice.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Opioid-Related Disorders
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Enrollment
0 (false)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Buprenorphine
Primary Outcome Measure Information:
Title
Drug use
Title
Opioid withdrawal
Title
Opioid agonist effects
Title
Dose choice
10. Eligibility
Sex
All
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
48 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Please contact site for information.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Warren Bickel, Ph.D.
Organizational Affiliation
University of Vermont
Official's Role
Principal Investigator
Facility Information:
Facility Name
Treatment Research Center
City
Burlington
State/Province
Vermont
ZIP/Postal Code
05401
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Alternate-Day Buprenorphine Administration. Phase VIII - 9
We'll reach out to this number within 24 hrs